Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms
Clinical and Hematologic Risk Factors of Right Ventricular Dysfunction and Pulmonary Hypertension in Myeloproliferative Neoplasms
This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.
Studieoversigt
Status
Detaljeret beskrivelse
Myeloproliferative neoplasms (MPNs) are associated with an increased risk of pulmonary hypertension and right ventricular dysfunction. This observational study will include adults with confirmed polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
All participants will undergo clinical assessment, laboratory evaluation, and echocardiography to assess pulmonary artery systolic pressure and right ventricular systolic function (TAPSE, FAC, and tissue Doppler S').
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Esraa M Ahmed, Resident
- Telefonnummer: +20 10 99071931
- E-mail: esraamedhat449@gmail.com
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adult patients with confirmed myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) attending the Hematology Unit and Critical Care Department at Assiut University Hospital.
Beskrivelse
Inclusion Criteria:
- - Age 18 years or older
- Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis)
- Stable clinical condition
- Written informed consent
Exclusion Criteria:
- - Significant left-sided valvular heart disease
- Congenital heart disease
- COPD or interstitial lung disease causing pulmonary hypertension
- Poor echocardiographic window
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiver: CROSS_SECTIONAL
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Single cohort: Patients with myeloproliferative neoplasms
Adult patients with myeloproliferative neoplasms who will undergo clinical, laboratory, and echocardiographic assessment for pulmonary hypertension and right ventricular dysfunction. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prevalence of Pulmonary Hypertension in MPN Patients
Tidsramme: Baseline
|
PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m/s. Prevalence will be calculated. |
Baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prevalence of right ventricular dysfunction
Tidsramme: Baseline
|
Proportion of patients with right ventricular dysfunction defined by TAPSE <17 mm, RV fractional area change <35%, or tissue Doppler S' <9.5 cm/s |
Baseline
|
|
Pulmonary artery systolic pressure
Tidsramme: Baseline
|
Mean estimated pulmonary artery systolic pressure (mmHg) measured by echocardiography |
Baseline
|
|
Tricuspid annular plane systolic excursion (TAPSE)
Tidsramme: Baseline
|
Mean TAPSE value (mm) measured by echocardiography. |
Baseline
|
|
Right ventricular fractional area change
Tidsramme: Baseline
|
Mean right ventricular fractional area change (%) measured by echocardiography. |
Baseline
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Refaat f abdel all, prof, Critical care unit Internal Medicine Department, Assiut University Hospitals
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MPN-PH-RVD-Assiut-2026
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .